News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Scanlon Meghan
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/19/2023 |
4
| Scanlon Meghan (Director) has filed a Form 4 on Paragon 28, Inc.|
Txns:
| Granted 8,361 shares
@ $0 |
|
| 05/02/2022 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 606 shares
@ $42.11, valued at
$25.5k
Exercised 2,062 restricted stock units
@ $0 |
|
| 04/05/2022 |
4
| Scanlon Meghan (Director) has filed a Form 4 on Paragon 28, Inc.|
Txns:
| Granted 17,846 shares
@ $0 |
|
| 04/05/2022 |
3
| Scanlon Meghan (Director) has filed a Form 3 on Paragon 28, Inc. |
| 03/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/23/2022 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 229 shares
@ $42.55, valued at
$9.7k
Exercised 779 restricted stock units
@ $0 |
|
| 02/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/17/2022 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 388 shares
@ $44.01, valued at
$17.1k
Exercised 1,108 restricted stock units
@ $0
Granted 8,486 restricted stock units
@ $0
Granted 24,264 options to buy
@ $44.19, valued at
$1.1M
|
|
| 08/04/2021 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Granted 15,257 restricted stock units
@ $0 |
|
| 07/27/2021 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Sold 13,850 shares
@ $45.01, valued at
$623.4k
Exercised 13,850 options to buy
@ $23.41, valued at
$324.2k
|
|
| 06/28/2021 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Sold 16,450 shares
@ $44.03, valued at
$724.3k
Exercised 16,450 options to buy
@ $17.26, valued at
$283.9k
|
|
| 03/02/2021 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 299 shares
@ $38.78, valued at
$11.6k
Exercised 1,018 restricted stock units
@ $0 |
|
| 02/23/2021 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 223 shares
@ $38.03, valued at
$8.5k
Paid exercise price by delivering 338 shares
@ $39.2, valued at
$13.2k
Exercised 779 restricted stock units
@ $0
Exercised 1,159 restricted stock units
@ $0
Granted 3,940 options to buy
@ $0 |
|
| 02/19/2021 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 372 shares
@ $37.52, valued at
$14k
Granted 6,333 restricted stock units
@ $0
Granted 20,368 options to buy
@ $37.5, valued at
$763.8k
Exercised 1,111 restricted stock units
@ $0 |
|
| 02/17/2021 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 388 shares
@ $38.39, valued at
$14.9k
Exercised 1,107 restricted stock units
@ $0 |
|
| 07/09/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2020 |
4
| Scanlon Meghan (SVP,Pres,Urology Pelvic Health) has filed a Form 4 on BOSTON SCIENTIFIC CORP|
Txns:
| Paid exercise price by delivering 626 shares
@ $35.99, valued at
$22.5k
Exercised 2,061 restricted stock units
@ $0 |
|
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/18/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|
|